The use of artemether-lumefantrine for the treatment of uncomplicated plasmodium vivax malaria

PLoS Neglected Tropical Diseases

Volumn 5, Issue 12, 2011, Pages

  Bassat, Quique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG RESPONSE; HUMAN; INFECTION PREVENTION; LIFE CYCLE; PARASITE CLEARANCE; PLASMODIUM VIVAX MALARIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; PARASITOLOGY; PLASMODIUM VIVAX; REVIEW;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; PRIMAQUINE; TREATMENT OUTCOME;

EID: 84855254068     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001325     Document Type: Article

References (83)

1. Guerra C, Howes RE, Patil AP, Gething PW, Van Boeckel TP, et al. (2010) The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 4: e774 doi:10.1371/journal.pntd.0000774.
2. Mendis K, Sina BJ, Marchesini P, Carter R, (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106.
3. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555-566.
4. Nigatu W, Abebe M, Dejene A, (1992) Plasmodium vivax and P. falciparum epidemiology in Gambella, south-west Ethiopia. Trop Med Parasitol 43: 181-185.
5. Jima D, Getachew A, Bilak H, Steketee RW, Emerson PM, et al. (2010) Malaria indicator survey 2007, Ethiopia: coverage and use of major malaria prevention and control interventions. Malar J 9: 58.
6. Animut A, Mekonnen Y, Shimelis D, Ephraim E, (2009) Febrile illnesses of different etiology among outpatients in four health centers in Northwestern Ethiopia. Jpn J Infect Dis 62: 107-110.
7. Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, et al. (2009) Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis 200: 1465-1469.
8. Miller LH, Mason SJ, Clyde DF, McGinniss MH, (1976) The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295: 302-304.
9. Rosenberg R, (2007) Plasmodium vivax in Africa: hidden in plain sight? Trends Parasitol 23: 193-196.
10. Mercereau-Puijalon O, Ménard D, (2010) Plasmodium vivax and the Duffy antigen: a paradigm revisited. Transfus Clin Biol 17: 176-183.
11. Price RN, Douglas NM, Anstey NM, (2009) New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22: 430-435.
12. Bassat Q, Alonso PL, (2011) Defying malaria: fathoming severe Plasmodium vivax disease. Nature Med 1: 48-49.
13. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87.
14. Maguire JD, Baird JK, (2010) The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies. Ann Trop Med Parasitol 104: 283-301.
15. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, et al. (2005) Plasmodium vivax malaria. Emerg Infect Dis 11: 132-134.
16. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128 doi:10.1371/journal.pmed.0050128.
17. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, et al. (2008) Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5: e127 doi:10.1371/journal.pmed.0050127.
18. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, (2010) Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405-416.
19. Baird JK, (2009) Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 22: 508-534.
20. World Health Organization (2010) WHO guidelines for the treatment of malaria, 2nd ed Geneva World Health Organization Available: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html Accessed 29 March 2010.
21. Ashton RA, Kefyalew T, Tesfaye G, Counihan H, Yadeta D, et al. (2010) Performance of three multi-species rapid diagnostic tests for diagnosis of Plasmodium falciparum and Plasmodium vivax malaria in Oromia Regional State, Ethiopia. Malar J 9: 297.
22. Osman MM, Nour BY, Sedig MF, De Bes L, Babikir AM, et al. (2010) Informed decision-making before changing to RDT: a comparison of microscopy, rapid diagnostic test and molecular techniques for the diagnosis and identification of malaria parasites in Kassala, eastern Sudan. Trop Med Int Health 15: 1442-1448.
23. Alvarez G, Piñeros JG, Tobón A, Ríos A, Maestre A, et al. (2006) Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med 76: 605-609.
24. Galappaththy GN, Omari AA, Tharyan P, (2007) Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 1: CD004389.
25. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ, (1994) Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169: 932-935.
26. Naing C, Aung K, Win DK, Wah MJ, (2010) Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Trans R Soc Trop Med 104: 695-705.
27. Baird JK, (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083.
28. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, et al. (2010) Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J 9: 52.
29. Srivastava HC, Radav RS, Joshi H, Valecha N, Mallick PK, et al. (2008) Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates. Ann Trop Med Parasitol 102: 471-480.
30. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, et al. (2008) Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health 13: 91-98.
31. Kurcer MA, Simsek Z, Kurcer Z, (2006) The decreasing efficacy of chloroquine in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Ann Trop Med Parasitol 100: 109-113.
32. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, et al. (2007) Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 13: 1125-1126.
33. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, et al. (2001) Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg 65: 90-93.
34. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P, (2011) Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg 84: 137-140.
35. Ketema T, Bacha K, Birhanu T, Petros B, (2009) Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J 8: 177.
36. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, et al. (2008) Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 7: 220.
37. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al. (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927-933.
38. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, et al. (2000) Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685.
39. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 3: CD007483.
40. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, et al. (2010) Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 10: 762-769.
41. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, et al. (2009) Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 9: 249.
42. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, et al. (2006) Efficacy and safety of the six-dose regimen of arthemeter-lumefrantrine in pediatrics with uncomplicated plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 74: 991-998.
43. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, et al. (2008) A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med 5: e253 doi:10.1371/journal.pmed.0050253.
44. Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G, (2008) A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J Infect Dev Ctries 2: 135-139.
45. Falade C, Manyando C, (2009) Safety profile of Coartem: the evidence base. Malar J 8 (Suppl 1): S6.
46. Kokwaro G, Mwai L, Nzila A, (2007) Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 8: 75-94.
47. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, et al. (2011) Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612-620.
48. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ, (2000) Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 44: 697-704.
49. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, et al. (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66: 472-484.
50. Krishna S, White NJ, (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 30: 263-299.
51. Bustos DG, Lazaro JE, Gay F, Pottier A, Laracas CJ, et al. (2002) Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. Trop Med Int Health 7: 584-591.
52. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, et al. (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582-596.
53. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, et al. (2008) Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 52: 1052-1061.
54. Stepniewska K, White NJ, (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52: 1589-1596.
55. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ, (2004) Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 89: 351-356.
56. Li X, Li C, Che L, Liu X, Li Z, et al. (1999) [Observation on efficacy of artemether compound against vivax malaria.] Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 17: 175-177.
57. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, et al. (2007) Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 45: 111-114.
58. Hutagulung R, Paiphun L, Ashley EA, McGready R, Brockman A, et al. (2005) A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malaria J 4: 46-52.
59. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545-2557.
60. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, et al. (2001) A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 645: 247-256.
61. Mayxay M, Khanthavong M, Lindegårdh N, Keola S, Barends M, et al. (2005) Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin Infect Dis 39: 1139-1147.
62. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757-765.
63. Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, et al. (2004) Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Trop Med Int Health 9: 1175-1183.
64. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, et al. (2010) Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10: 673-681.
65. Thapa S, Hollander J, Linehan M, Cox-Singh J, Bista MB, et al. (2007) Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal. Am J Trop Med Hyg 77: 423-430.
66. van den Broek IV, Maung UA, Peters A, Liem L, Kamal M, et al. (2005) Efficacy of chloroquine+sulfadoxine-pyrimethamine, mefloquine+artesunate and artemether+lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. Trans R Soc Trop Med Hyg 99: 727-735.
67. Van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, et al. (1999) Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 60: 936-942.
68. Karbwang J, Na-Bangchang K, Thanavibul A, Mull R, Gathmann I, (2000) Dose-finding study of the efficacy of fixed-combination artemether/lumefantrine for the treatment of multidrug-resistant Plasmodium falciparum malaria in Thailand. Clin Drug Invest 19: 343-348.
69. Makanga M, Krudsood S, (2009) The clinical efficacy of artemether/lumefantrine (Coartem). Malar J 8 (Suppl 1): S5.
70. Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P, et al. (2006) Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Trop 100: 41-53.
71. Pukrittayakamee S, Imwong M, Singhasivanon P, Stepniewska K, Day NJ, et al. (2008) Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am J Trop Med Hyg 79: 378-384.
72. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, et al. (2010) Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar J 9: 48.
73. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, et al. (2009) Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxinepyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J 26: 204.
74. Bangchang KN, Karbwang J, Back DJ, (1992) Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 44: 587-590.
75. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM, (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59: 429-442.
76. McKenzie FE, Wongsrichanalai C, Magill AJ, Forney JR, Permpanich B, et al. (2006) Gametocytemia in Plasmodium vivax and Plasmodium falciparum infections. J Parasitol 92: 1281-1285.
77. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, et al. (2004) Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 48: 1329-1334.
78. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim K, et al. (2003) The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. Am J Trop Med Hyg 68: 620-623.
79. Méndez F, Muñoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, et al. (2002) Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156: 230-238.
80. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, et al. (2008) A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 7: 237.
81. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, et al. (2007) Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45: 1453-1461.
82. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, et al. (2007) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2: e20 doi:10.1371/journal.pctr.0020020.
83. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, et al. (2008) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 3: e2390 doi:10.1371/journal.pone.0002390.